Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation
- 2 November 2021
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 21 (2) , 372-385
Abstract
In the Sponsor Responsibilities—Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Draft Guidance for Industry (June 2021) the Food and Drug Administration recommends that sponsors develop a Safety Surveillance Plan as a key element of a systematic approach to safety surveillance and describes two possible approaches to assess the aggregate safety data. One approach regularly analyzes unblinded serious adverse events (SAEs) by treatment group. The alternative approach prespecifies estimated background rates for anticipated SAEs in the study population (e.g., myocardial infarctions in an older adult population). If the event rate in the blinded data from the study population exceeds a “trigger rate,” then an unblinded analysis by treatment group is conducted. The Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method has been previously described and offers a quantitative approach for assessing blinded events. In this article we provide a procedural workflow for blinded review of safety data that is consistent with the unblinding “trigger approach” for aggregate safety review. In addition, this publication contextualizes the use of BDRIBS within the broader safety surveillance framework, extends the method to allow for multiple studies, and offers examples of its use in various settings via an R‐Shiny application that allows for dynamic visualization and assessment.Keywords
This publication has 11 references indexed in Scilit:
- The importance of cross‐disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessmentsPharmaceutical Statistics, 2019
- Bayesian detection of potential risk using inference on blinded safety dataPharmaceutical Statistics, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Blinded Safety Signal Monitoring for the FDA IND Reporting Final Rule2016
- A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded DataTherapeutic Innovation & Regulatory Science, 2016
- Monitoring potential adverse event rate differences using data from blinded trials: the canary in the coal mineStatistics in Medicine, 2016
- Control charts for monitoring accumulating adverse event count frequencies from single and multiple blinded trialsStatistics in Medicine, 2016
- Safety Monitoring in Clinical TrialsPharmaceutics, 2013
- Continuous safety monitoring for randomized controlled clinical trials with blinded treatment informationContemporary Clinical Trials, 2011
- Summarizing historical information on controls in clinical trialsClinical Trials, 2010